Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review.

These findings support the current recommendation for using CNI as first-line treatment for children with SRNS whilst genetic analyses are pending. This would allow assessment of treatment response even in cases later established as genetic ensuring that benefits on kidney function are balanced with treatment toxicity.